Trial Profile
An Open-label, Multi-center, Randomized Study Comparing the Effects of Oral Hypoglycemic Agents on Viral Kinetics of Chronic Hepatitis C Patients Receiving Pegylated Interferon Alfa 2b Plus Ribavirin
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Acarbose (Primary) ; Metformin (Primary) ; Pioglitazone (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Insulin resistance
- Focus Therapeutic Use
- 26 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Dec 2009 New trial record